2018 - 2026
Need a report that reflects how COVID-19 has impacted this market and its growth?
The European Cancer Biomarkers Market is expected to register a CAGR of nearly 11.6% during the forecast period with a revenue of approximately USD 4,008 million in 2020 and expected to reach USD 7,764 million by 2026. Certain factors that are driving the growth of the market include the increased burden of cancer and increasing focus on innovative drug development.
With the rising of the COVID-19, several companies are increased their focus on the development of drug or vaccine for COVID-19 and that has shown a negative impact on interventional and other cancer biomarker related clinical trials which have been stopped as a result of the COVID-19 virus situation across the globe and it is observed that it will have a negative impact for the short period of time. The companies such as Pfizer, Eli Lilly, and Bristol-Myers Squibb have also announced that they had halted the new clinical trials as a result of COVID-19. As per Pfizer's announcement, in late March 2020, paused the recruitment portion of certain global interventional clinical trial studies and to avoid adding to the demands on the healthcare system during the peak of the crisis.
As per the estimates of the Globocan 2020, there were 467,965 new cases of cancer in France, and there had been 185,621 deaths due to it. According to the Fondation de France, cancer affects over 350,000 people every year and kills close to 150,000, representing roughly 1/3 of total deaths. Due to this high prevalence of cancer, increasing efforts are being made in R&D for the development of novel cancer therapeutics and diagnostics.
Cancer biomarker is thus found playing a pivotal role in risk assessment and early diagnosis. Biomarkers, particularly those associated with genetic factors, offer a quantitative way to determine when individuals are predisposed to some form of cancer. These biomarkers have been developed for almost all cancers with a high prevalence rate. Some of the examples for such biomarkers are mutation on KRAS, p53, EGFR, erbB2 for colorectal, esophageal, liver and pancreatic cancer, and BRCA1 and BRCA2 for breast and ovarian cancer.
Biomarker based early detection enables sensitive and cost-effective testing, which is expected to reduce cancer mortality. The biomarker’s potential to assess the risk precisely has helped in improving the adoption for the technology, which has led to market expansion.
Furthermore, in November 2019, Hitachi and Centre Léon Bérard cancer center in France promoted R&D aimed at improving the efficiency of diagnosis and treatment of cancer and established a new research laboratory called Hitachi Lyon Lab. The research also includes identification of biomarkers exploiting genomic data in the context of resistance, which may allow to predict responses and prognoses upon radiation treatment. Hence the high burden of cancer and increasing R&D activities are expected to boost the overall growth of the market.
Scope of the report
As per the scope of the report, Biomarkers are chemical, physical, or biological parameters, which can be used to indicate disease states. Oncology biomarkers offer high-speed, non-invasive cancer diagnoses, and enhance cancer detection and screening. The Europe cancer biomarkers market is segmented by disease (prostate cancer, breast cancer, lung cancer, colorectal cancer, cervical cancer, and other diseases), type (protein biomarkers, genetic biomarkers, and other types), profiling technology (omics technology, imaging technology, immunoassays, and cytogenetics). The report offers the value (in USD million) for the above segments.
|By Profiling Technology|
Key Market Trends
Lung Cancer Segment is Expected to Hold a Major Market Share in the Europe Cancer Biomarkers Market
Lung cancer is caused by the uncontrolled growth of abnormal cells that multiply in one lung or both lungs. Although it can affect people who never smoked, people who smoke have the highest risk of lung cancer. The risk of lung cancer increases with the duration and number of cigarettes that the patient smoked. Other risk factors include occupational or environmental exposure to secondhand smoke, asbestos, certain metals, some organic chemicals, radiation, air pollution, and diesel exhaust.
With the rising cancer cases, there are millions of people that are being infected with COVID-19 around the globe. Since the focus of healthcare facilities was shifted to COVID-19, cancer patients' treatment was restricted for a certain period, followed by cancer biomarker-related clinical trials were being halted for a less period of time that showed a slight negative impact on the overall market.
According to the estimates of Globocan 2020, there were 457,960 new cancer cases in the United Kingdom while prostate, breast, lung, colon, and skin cancer are the most common types of cancer detected in the United Kingdom. Based on the same estimates there were 415,269 new cases of cancer in Italy and about 174,759 deaths. Therefore, owing to the rising number of cases of cancer, the cancer biomarkers market in Europe is expected to record a substantial growth over the forecast period.
Some of the leading biomarkers for lung cancer include CYFRA 21-1, Plasma Kallikrein (KLKB1), Serum Amyloid A (SAA), Haptoglobin β Chain (Hp β), Complement Component 9 (C9), Endoglin (CD105), Peroxiredoxin 1 (PRX1), and Pro-gastrin-releasing Peptide (proGRP). As most of the aforementioned biomarkers are commercially available, the intensity of competition is already high in this segment. Therefore the early diagnosis, coupled with the rising level of awareness among people, may lead to the healthy growth of the market studied.
To understand key trends, Download Sample Report
The European cancer biomarkers market is highly competitive and consists of a few major players. Some of the companies which are currently dominating the market are Abbott Laboratories Inc., Agilent Technologies, Ambry Genetics, Biomerieux, Celera Corporation (Quest Diagnostics), F. Hoffmann-La Roche Ltd, Hologic Inc., Illumina Inc., and Thermo Fisher Scientific, among others, hold substantial shares in the market. Furthermore, some of the major market players, such as Novartis and Gilead in cancer therapy, are from Europe, and it is one of the factors that boosted the R&D activities in the region.
- In Nov 2020, Agilent Technologies has announced the launch of the Biomarker Pathologist Training Program, a global initiative created to empower pathologists to score biomarkers accurately and confidently.
- In March 2020, Proteomedix, has announced that Proclarix, its blood-based test for prostate cancer diagnosis, has now been made commercially available in Europe. Proclarix combines proprietary biomarkers and a risk score that accurately identifies an individual patient’s risk for clinically significant prostate cancer.
Table of Contents
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Burden of Cancer and Higher Acceptance for Treatment
4.2.2 Increasing Focus on Innovative Drug Development
4.3 Market Restraints
4.3.1 High Cost of Diagnosis
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Disease
5.1.1 Prostate Cancer
5.1.2 Breast Cancer
5.1.3 Lung Cancer
5.1.4 Colorectal Cancer
5.1.5 Cervical Cancer
5.1.6 Other Diseases
5.2 By Type
5.2.1 Protein Biomarkers
5.2.2 Genetic Biomarkers
5.2.3 Other Types
5.3 By Profiling Technology
5.3.1 OMICS Technology
5.3.2 Imaging Technology
5.4 By Geography
220.127.116.11 Germany (By Disease, By Type, and By Profiling Technology)
18.104.22.168 United Kingdom (By Disease, By Type, and By Profiling Technology)
22.214.171.124 France (By Disease, By Type, and By Profiling Technology)
126.96.36.199 Italy (By Disease, By Type, and By Profiling Technology)
188.8.131.52 Spain (By Disease, By Type, and By Profiling Technology)
184.108.40.206 Rest of Europe (By Disease, By Type, and By Profiling Technology)
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Illumina Inc
6.1.2 Creative Diagnostics
6.1.3 Abbott Laboratories Inc.
6.1.4 Agilent Technologies
6.1.5 Biomerieux SA
6.1.6 Quest Diagnostics
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 Hologic Inc
6.1.9 Thermo Fisher Scientific Inc.
6.1.11 Ambry Genetics (Konica Minolta Inc.)
6.1.12 Johnson & Johnson Services, Inc
6.1.13 Epigenomics AG
6.1.14 Qiagen AG
6.1.15 Bio-Rad Laboratories, Inc.
6.1.16 PerkinElmer, Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Europe Cancer Biomarkers Market market is studied from 2018 - 2026.
What is the growth rate of Europe Cancer Biomarkers Market?
The Europe Cancer Biomarkers Market is growing at a CAGR of 11.6% over the next 5 years.
What is Europe Cancer Biomarkers Market size in 2018?
The Europe Cancer Biomarkers Market is valued at 4008 Million USD in 2018.
What is Europe Cancer Biomarkers Market size in 2026?
The Europe Cancer Biomarkers Market is valued at 7764 Million USD in 2026.
Who are the key players in Europe Cancer Biomarkers Market?
- Abbott Laboratories Inc
- F. Hoffmann-La Roche Ltd
- Illumina Inc
- Thermo Fisher Scientific
Are the major companies operating in Europe Cancer Biomarkers Market.